Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALPN

ALPN - Alpine Immune Sciences Inc Stock Price, Fair Value and News

35.97USD+0.75 (+2.13%)Market Closed
Watchlist

Market Summary

USD35.97+0.75
Market Closed
2.13%

ALPN Alerts

  • 1 major insider sales recently.

ALPN Stock Price

View Fullscreen

ALPN RSI Chart

ALPN Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-36.66

Price/Sales (Trailing)

67.85

EV/EBITDA

-37.18

Price/Free Cashflow

-27.03

ALPN Price/Sales (Trailing)

ALPN Profitability

EBT Margin

-183.32%

Return on Equity

-35.27%

Return on Assets

-23.7%

Free Cashflow Yield

-3.7%

ALPN Fundamentals

ALPN Revenue

Revenue (TTM)

30.8M

Rev. Growth (Yr)

20.03%

Rev. Growth (Qtr)

16.87%

ALPN Earnings

Earnings (TTM)

-57.0M

Earnings Growth (Yr)

11.69%

Earnings Growth (Qtr)

10.9%

Breaking Down ALPN Revenue

Last 7 days

7.6%

Last 30 days

52.9%

Last 90 days

133.6%

Trailing 12 Months

292.2%

How does ALPN drawdown profile look like?

ALPN Financial Health

Current Ratio

3.81

ALPN Investor Care

Shares Dilution (1Y)

26.54%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202325.8M29.1M30.8M0
202233.9M32.0M31.8M30.1M
202111.4M18.0M24.6M23.4M
20202.8M3.0M4.6M9.3M
2019963.8K1.2M1.5M1.7M
20181.5M1.1M910.2K705.0K
20173.0M3.0M2.3M1.7M
20161.1M1.7M2.3M3.0M
2015000492.0K

Tracking the Latest Insider Buys and Sells of Alpine Immune Sciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 26, 2024
rickey james paul
acquired
977,844
8.30342
117,764
see remarks
Jan 26, 2024
rickey james paul
sold
-2,745,830
23.3164
-117,764
see remarks
Jan 25, 2024
rickey james paul
sold
-5,192
22.00
-236
see remarks
Jan 25, 2024
rickey james paul
acquired
1,536
6.51
236
see remarks
Jan 18, 2024
cui xiangmin
acquired
15,729,300
12.74
1,234,640
-
Jan 18, 2024
decheng capital china life sciences usd fund iii, l.p.
acquired
15,729,300
12.74
1,234,640
-
Jan 11, 2024
thompson peter a.
acquired
1,850,500
12.74
145,251
-
Jan 11, 2024
orbimed advisors llc
acquired
1,850,500
12.74
145,251
-
Jan 04, 2024
durand remy
acquired
-
-
31,200
chief business officer
Jan 04, 2024
gold mitchell
acquired
-
-
96,000
executive chairman and ceo

1–10 of 50

Which funds bought or sold ALPN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
2.17
127,095
308,486
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
20.83
16,170,000
32,161,000
-%
Feb 15, 2024
Virtus ETF Advisers LLC
new
-
93,470
93,470
0.06%
Feb 15, 2024
BARCLAYS PLC
added
779
1,427,000
1,531,000
-%
Feb 15, 2024
Exome Asset Management LLC
new
-
3,306,910
3,306,910
3.27%
Feb 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
added
30.47
2,415,070
4,476,070
0.72%
Feb 15, 2024
JANE STREET GROUP, LLC
added
281
1,115,410
1,323,780
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
381
381
-%
Feb 15, 2024
Legal & General Group Plc
added
15.62
240,487
500,573
-%
Feb 14, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.
new
-
13,620,100
13,620,100
0.03%

1–10 of 48

Are Funds Buying or Selling ALPN?

Are funds buying ALPN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALPN
No. of Funds

Unveiling Alpine Immune Sciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
omega fund vi, l.p.
0.0%
0
SC 13G/A
Feb 14, 2024
paradigm biocapital advisors lp
5.5%
3,176,743
SC 13G/A
Feb 14, 2024
lynx1 capital management lp
6.6%
3,813,926
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
4.39%
2,550,000
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
9.99%
5,903,234
SC 13G/A
Feb 14, 2024
great point partners llc
6.37%
3,703,433
SC 13G/A
Feb 02, 2024
blackrock inc.
5.3%
3,058,498
SC 13G
Dec 29, 2023
orbimed advisors llc
4.6%
2,680,496
SC 13D/A
Nov 22, 2023
frazier life sciences viii, l.p.
4.7%
2,829,366
SC 13D/A
Nov 14, 2023
decheng capital china life sciences usd fund iii, l.p.
11.1%
6,582,380
SC 13D/A

Recent SEC filings of Alpine Immune Sciences Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
8-K
Current Report
Feb 02, 2024
SC 13G
Major Ownership Report
Jan 29, 2024
4
Insider Trading
Jan 26, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of ALPN?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Alpine Immune Sciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.3B
6.8B
-16.59% -47.80%
-7.7
5.3
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
-23.99% -31.71%
-43.66
10.51
76.23% 61.08%
16.4B
2.4B
-4.89% -18.90%
98.05
6.79
15.42% 18.43%
13.3B
3.7B
-7.62% -26.87%
22.19
3.59
8.87% 75.42%
MID-CAP
7.7B
396.6M
-2.06% 34.31%
-14.57
19.42
425.83% 18.94%
6.3B
-
-3.85% 226.12%
-10.06
60.35
54.84% -25.61%
4.5B
240.7M
-19.08% -10.99%
-15.05
18.56
-1.03% -92.09%
4.0B
726.4M
-12.60% 32.37%
-64.55
5.45
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.3
14.41
440.80% -27.84%
SMALL-CAP
2.0B
398.2M
-3.38% -9.50%
28.08
5.03
85.90% -14.05%
752.9M
983.7M
-9.17% -57.89%
-1.38
0.77
-50.36% 17.16%
217.0M
4.9M
-14.18% -58.18%
-1.32
44.39
-57.57% 50.48%
154.8M
881.7K
289.54% 381.25%
-3.26
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Alpine Immune Sciences Inc News

Latest updates
InvestorsObserver31 hours ago

Alpine Immune Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue16.9%10,043,0008,593,0009,387,0002,776,0008,367,0005,292,00013,629,0004,530,0008,516,0007,193,0003,204,0005,643,0001,913,000688,0001,091,000884,000289,000567,000487,667408,333329,000
Operating Expenses1.4%24,593,00024,248,00024,979,00023,145,00022,199,00021,781,00021,086,00019,906,00021,779,00017,924,00013,693,00012,104,0008,884,00010,440,0006,656,0007,901,00011,999,00012,719,00012,695,00011,445,00012,386,000
  S&GA Expenses8.7%5,443,0005,007,0005,398,0004,389,0004,610,0004,194,0004,775,0004,544,0003,470,0003,290,0003,256,0003,049,0002,728,0003,344,0001,778,0002,102,0002,467,0002,553,0002,345,0002,514,0001,857,000
  R&D Expenses-0.5%19,150,00019,241,00019,581,00018,756,00017,589,00017,587,00016,311,00015,362,00018,309,00014,634,00010,437,0009,055,0006,156,0007,096,0004,878,0005,799,0009,532,00010,166,00010,350,0008,931,00010,529,000
EBITDA Margin7.8%-1.81-1.96-2.33-1.81-1.62-1.61-1.36-2.09-1.62-1.81-2.76-2.85---------
Interest Expenses-100.0%-28,00070,00087,000105,000130,000154,000178,000203,000218,000217,000215,000214,000226,000120,000141,00066,00061,00070,00076,00082,000
Income Taxes----548,000-1,778,0004,000-298,00080,000131,000----6,000------61,000-
Earnings Before Taxes10.9%-11,722,000-13,156,000-13,266,000-18,316,000-13,273,000-16,320,000-7,523,000-15,465,000-13,414,000-10,898,000-10,643,000-6,342,000-6,137,000-9,934,000--6,140,000-11,475,000-11,856,000-12,381,000-11,196,000-12,139,000
EBT Margin8.0%-1.83-1.99-2.37-1.84-1.65-1.65-1.40-2.15-1.68-1.89-2.89-2.99---------
Net Income10.9%-11,722,000-13,156,000-13,266,000-18,864,000-13,273,000-18,098,000-7,527,000-15,167,000-13,494,000-11,029,000-10,643,000-6,342,000-6,137,000-9,928,000-5,533,000-6,140,000-11,475,000-11,856,000-12,381,000-11,135,000-12,139,000
Net Income Margin7.9%-1.85-2.01-2.46-1.92-1.70-1.70-1.39-2.15-1.69-1.90-2.89-2.99---------
Free Cashflow14.0%-15,799,000-18,370,000-26,245,000-16,902,000-16,403,000-16,284,0005,423,000-14,778,00030,134,000-14,712,000-16,010,000-9,837,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-4.9%24125326228729221623425623316013014415410350.0054.0065.0070.0067.0055.0065.00
  Current Assets-4.8%19720719924125317217619218414010010714391.0038.0042.0052.0057.0065.0054.0063.00
    Cash Equivalents-44.3%19.0034.0014.0013.0012725.0035.0068.0076.0019.0013.0035.0014188.0025.0017.0018.0016.0042.0011.0012.00
  Net PPE-8.3%2.002.002.002.002.002.002.002.001.002.002.002.002.002.002.002.001.001.001.001.001.00
Liabilities-5.4%79.0083.0093.0010711011611913511111677.0082.0087.0086.0025.0025.0030.0025.0011.0010.0010.00
  Current Liabilities-3.0%52.0053.0057.0058.0068.0063.0068.0070.0064.0060.0043.0041.0036.0028.005.009.0014.0013.009.008.007.00
  Long Term Debt------1.002.003.005.006.006.008.009.0010.008.005.005.001.002.002.003.00
    LT Debt, Current---2.003.005.005.005.005.005.005.004.003.001.000.002.000.00-2.002.002.002.00
    LT Debt, Non Current------1.002.003.005.006.006.008.009.0010.008.005.005.001.002.002.003.00
Shareholder's Equity-4.6%16216917017918210011512112344.0053.0062.0067.0016.0025.0029.0035.0045.0057.0045.0055.00
  Retained Earnings-4.7%-262-250-237-223-205-191-173-166-151-137-126-115-109-103-93.46-87.93-81.79-70.31-58.45-46.07-34.94
  Additional Paid-In Capital0.9%42442040740438929329028727418118017817712011811711711611591.0090.00
Shares Outstanding0.3%49.0049.0048.0046.0032.0030.0030.0030.0024.0024.0024.0021.00---------
Float------132---105---50.00---21.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations12.7%-15,798-18,091-26,152-16,786-16,348-16,0695,449-14,72930,134-14,682-15,971-9,349-5,39254,519-9,694-5,671-10,575-7,877-11,223-9,398-7,372
  Share Based Compensation1.3%2,6542,6212,5522,4692,5552,3352,2891,4601,6381,5451,5979499731,232986780825682754731544
Cashflow From Investing-101.8%-53529,32828,350-107,89925,7906,564-37,803-4,285-62,51520,866-6,546-96,8491,8439,05713,1304,38810,863-17,58719,0999,13615,774
Cashflow From Financing-85.7%1,2018,398-1,08711,54392,816-1,020-65010,87389,6809.00202-11.0056,3902.005,000-1,646-50923,118-500-498

ALPN Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]Collaboration [Member]Collaboration [Member]Collaboration [Member]Collaboration [Member]
Collaboration revenue$ 10,043$ 8,367$ 28,023$ 27,288
Operating expenses:    
Research and development19,15017,58957,97251,487
General and administrative5,4434,61015,84813,579
Total operating expenses24,59322,19973,82065,066
Loss from operations(14,550)(13,832)(45,797)(37,778)
Other income (expense):    
Interest income2,8916647,8371,123
Interest expense0(105)(98)(389)
Other, net(63)0(86)(72)
Loss before taxes(11,722)(13,273)(38,144)(37,116)
Income tax expense000(1,782)
Net loss(11,722)(13,273)(38,144)(38,898)
Comprehensive income (loss):    
Unrealized gain (loss) on investments170(307)677(1,385)
Unrealized (loss) gain on foreign currency translation(60)7(96)(11)
Comprehensive loss$ (11,612)$ (13,573)$ (37,563)$ (40,294)
Weighted-average shares used to compute basic net loss per share (in shares)49,222,34431,574,35848,286,20331,559,886
Weighted-average shares used to compute diluted net loss per share (in shares)49,222,34431,574,35848,286,20331,559,886
Basic net loss per share (in dollars per share)$ (0.24)$ (0.42)$ (0.79)$ (1.23)
Diluted net loss per share (in dollars per share)$ (0.24)$ (0.42)$ (0.79)$ (1.23)

ALPN Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 18,981$ 13,376
Short-term investments174,472224,265
Accounts receivable219392
Prepaid expenses and other current assets3,7432,960
Total current assets197,415240,993
Restricted cash, noncurrent254254
Property and equipment, net1,5331,584
Operating lease, right-of-use asset7,6978,219
Long-term investments33,50235,481
Deferred tax asset146155
Total assets240,547286,686
Current liabilities:  
Accounts payable3,0684,286
Accrued liabilities17,78814,003
Deferred revenue, current30,09235,571
Operating lease liability, current870756
Current portion of long-term debt03,380
Total current liabilities51,81857,996
Deferred revenue, noncurrent17,81239,185
Operating lease liability, noncurrent9,28610,085
Total liabilities78,916107,266
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; zero shares issued and outstanding at September 30, 2023 and December 31, 202200
Common stock, $0.001 par value per share; 200,000,000 shares authorized at September 30, 2023 and December 31, 2022; 49,274,160 shares issued and outstanding at September 30, 2023; 47,234,900 shares issued and 45,984,433 shares outstanding at December 31, 20224946
Treasury stock, at cost; zero and 1,250,467 shares at September 30, 2023 and December 31, 2022, respectively00
Additional paid-in capital424,227404,456
Accumulated other comprehensive loss(540)(1,121)
Accumulated deficit(262,105)(223,961)
Total stockholders’ equity161,631179,420
Total liabilities and stockholders’ equity$ 240,547$ 286,686
ALPN
Alpine Immune Sciences, Inc., a clinical-stage company, focuses on immune therapeutics. The company has strategic collaborations immunotherapies via protein engineering technologies with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept (ALPN-303), which is in a phase 1b, open-label study of povetacicept in autoimmune cytopenias, including immune thrombocytopenia, warm autoimmune hemolytic anemia, and cold agglutinin disease; and in phase 1b/2a, open-label study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, lupus nephritis, and primary membranous nephropathy. The company is also developing Acazicolcept (ALPN-101), which is in a phase 2 study of acazicolcept in patients with Systemic Lupus Erythematosus. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEwww.alpineimmunesciences.com
 EMPLOYEES126

Alpine Immune Sciences Inc Frequently Asked Questions


What is the ticker symbol for Alpine Immune Sciences Inc? What does ALPN stand for in stocks?

ALPN is the stock ticker symbol of Alpine Immune Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Alpine Immune Sciences Inc (ALPN)?

As of Thu Feb 29 2024, market cap of Alpine Immune Sciences Inc is 2.05 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers.

What is the fair value of ALPN stock?

You can check ALPN's fair value in chart for subscribers. The fair value of Alpine Immune Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Alpine Immune Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALPN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Alpine Immune Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether ALPN is over valued or under valued. Whether Alpine Immune Sciences Inc is cheap or expensive depends on the assumptions which impact Alpine Immune Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALPN.

What is Alpine Immune Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, ALPN's PE ratio (Price to Earnings) is -35.89 and Price to Sales (PS) ratio is 66.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALPN PE ratio will change depending on the future growth rate expectations of investors.